These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1534 related items for PubMed ID: 25307619

  • 1. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 2. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 3. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 4. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 5. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [Abstract] [Full Text] [Related]

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jan; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic performance of 18F-choline PET-CT in prostate cancer.
    Samper Ots P, Luis Cardo A, Vallejo Ocaña C, Cabeza Rodríguez MA, Glaria Enríquez LA, Couselo Paniagua ML, Olivera Vegas J.
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [Abstract] [Full Text] [Related]

  • 8. Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.
    Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira JM, Cózar-Olmo JM, Rodríguez-Fernández A.
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [Abstract] [Full Text] [Related]

  • 9. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G, Di Pierro GB, Papalia R, Sciuto R, Rea S, Ferriero M, Guaglianone S, Maini CL, Gallucci M.
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [Abstract] [Full Text] [Related]

  • 10. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [Abstract] [Full Text] [Related]

  • 11. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 13. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [Abstract] [Full Text] [Related]

  • 15. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
    Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
    [Abstract] [Full Text] [Related]

  • 16. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M, Evangelista L, Hodolič M, Mariani G, Baseric T, Bodanza V, Saladini G, Volterrani D, Cervino AR, Gregianin M, Puccini G, Guidoccio F, Fettich J, Borsatti E.
    J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
    Tan H, Joseph D, Loh NK, McCarthy M, Leong E, Siew T, Segard T, Morandeau L, Trevenen M, Francis RJ.
    J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
    [Abstract] [Full Text] [Related]

  • 18. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [Abstract] [Full Text] [Related]

  • 19. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
    Couñago F, Recio M, Maldonado A, Del Cerro E, Díaz-Gavela AA, Thuissard IJ, Sanz-Rosa D, Marcos FJ, Olaciregui K, Mateo M, Cerezo L.
    Cancer Imaging; 2016 Dec 07; 16(1):42. PubMed ID: 27927229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.